-
Immunicum is advancing a novel immuno-oncology approach to treat solid tumors through its lead program ilixadencel
Immunicum is listed on NASDAQ Stockholm under the ticker IMMU
Tweets by @Immunicum
Tweets by ImmunicumPress Releases
Immunicum AB (publ) Announces Appointment of Peter Hein as Interim Chief Financial Officer
13 May 2020Immunicum AB (publ) Receives Regenerative Medicine Advanced Therapy Designation from FDA for Ilixadencel in Kidney Cancer
06 May 2020Report from the Annual General Meeting of Immunicum AB (publ) on April 28, 2020
28 Apr 2020
News
-
ASCO Post Article / Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer
12 Mar 2020 -
RedEye Fight Cancer Seminar Presentation
10 Mar 2020 -
Article in BioStock / Immunicum’s Advancements with Ilixadencel
26 Feb 2020 -
Immunicum Article in BioStock
12 Feb 2020 -
RedEye Interview with COO, Sijme Zeilemaker
12 Feb 2020
About us
Developing innovative cancer immunotherapies
Immunicum is advancing a novel cell-based approach to target solid tumors.
Learn more
